Brief: Healx And Ovid Therapeutics To Enter Strategic Partnership

Ovid Therapeutics

08/02/2022 13:33

Feb 8 (Reuters) - Ovid Therapeutics Inc  OVID.O :
    * HEALX AND OVID THERAPEUTICS TO ENTER STRATEGIC PARTNERSHIP
    * OVID THERAPEUTICS INC - OVID TO LICENSE GABOXADOL TO HEALX
    * OVID THERAPEUTICS INC - HEALX TO EXPLORE GABOXADOL IN
COMBINATION THERAPIES FOR FRAGILE X, OTHER INDICATIONS
    * OVID THERAPEUTICS - SHOULD HEALX EXERCISE ITS OPTION, CO
WILL
RECEIVE MILESTONE PAYMENTS FOR SPECIFIC CLINICAL, REGULATORY,
COMMERCIAL ACHIEVEMENTS
    * OVID THERAPEUTICS INC - ADDITIONALLY, HEALX WILL PAY OVID
TIERED
ROYALTIES ON NET SALES ASSOCIATED WITH MARKETED THERAPIES
CONTAINING GABOXADOL
    * OVID THERAPEUTICS INC - OVID WILL RETAIN OPTION TO BECOME
HEALX'S CO-DEVELOPMENT AND CO-COMMERCIALIZATION PARTNER
    * OVID THERAPEUTICS INC - WILL SHARE NET PROFITS AND LOSSES
IN
LIEU OF MILESTONES AND ROYALTY PAYMENTS
    * OVID THERAPEUTICS INC - DOES NOT PLAN TO CONDUCT FURTHER
TRIALS
WITH GABOXADOL

Source text for Eikon:  ID:nGNXc6qTPJ 
Further company coverage:  OVID.O 

 ((Reuters.Briefs@thomsonreuters.com;))